Skip to content

Clinical efficacy and safety study of Alexandrite laser treatment for the treatment of skin hyperpigmentation disorders

Clinical efficacy and safety study of Alexandrite laser treatment for the treatment of skin hyperpigmentation disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014833
Enrollment
Unknown
Registered
2018-02-08
Start date
2015-09-01
Completion date
Unknown
Last updated
2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

freckle

Interventions

Group 1:Picosecond laser (PicoSureTM) emerald laser treatment instrument
Group 2:Nanosecond laser (AccoladeTM) Q-switch emerald laser therapeutic apparatus

Sponsors

Fudan University Affiliated Huashan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) aged 18 to 65 years old, male or female; 2) clear clinical diagnosis, no treatment of epidermal benign pigmented skin diseases, such as: freckles; 3) Fitzpatrick Type III ~ V; 4) The subjects agreed not to undergo any facial dermatosis surgery or treatment other than the test treatment during the treatment and observation period; 5) Subjects can understand and follow the test requirements throughout the whole process and can cooperate fully; 6) Subject voluntarily participated in the study and signed an informed notification.

Exclusion criteria

Exclusion criteria: 1) there is a scar or mark in the treated part of the subject, which affects the observer of the curative effect; 2) Subjects with other skin diseases or infections on the face; 3) light-sensitive or may be caused by light-induced epilepsy; 4) oral administration of vitamin A drugs within six months; 5) have been exposed to sunlight within six months; 6) have a history of serious allergies or have a history of blood diseases, taking drugs that interfere with coagulation; 7) Subjects with immunocompromised persons; 8) subjects with hypertrophic scar or keloid history; 9) Subjects had previous adverse effects on prilocaine or lidocaine products (this exclusion does not apply to subjects not using prilocaine or lidocaine products); 10) subjects have severe cardiovascular, gastrointestinal, respiratory, endocrine or central nervous system disorders and mental disorders that may have adverse effects on this clinical trial; 11) Participants participated in other clinical studies within 30 days prior to the screening date (this subject is not eligible if participating in other clinical cosmetology studies within 6 months); 12) Subjects did not agree with contraceptive measures during the study period (medically acceptable methods of contraception: condom use, continuous use of oral contraceptives for more than 3 months, injection or implantation of contraceptive devices, placement of IUDs ( IUD); 13) pregnant or lactating female subjects; 14) Researchers think the subject is not fit to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
effective;

Secondary

MeasureTime frame
cure rate;Global Aesthetic Improvement Scale;degree of ache;satisfaction of patients;

Countries

China

Contacts

Public ContactTong Lin
ddlin@hotmail.com+86 13951902258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026